ALAR PHARMACEUTICALS INC has a total of 29 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2017. It filed its patents most often in Taiwan, WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are DIPHARMA S A, SELAMINE LTD and VAMVAKIDES ALEXANDRE.
# | Country | Total Patents | |
---|---|---|---|
#1 | Taiwan | 4 | |
#2 | WIPO (World Intellectual Property Organization) | 4 | |
#3 | Australia | 2 | |
#4 | Brazil | 2 | |
#5 | Canada | 2 | |
#6 | China | 2 | |
#7 | EPO (European Patent Office) | 2 | |
#8 | Republic of Korea | 2 | |
#9 | United States | 2 | |
#10 | Argentina | 1 | |
#11 | Chile | 1 | |
#12 | Colombia | 1 | |
#13 | Mexico | 1 | |
#14 | Peru | 1 | |
#15 | Philippines | 1 | |
#16 | Singapore | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Name | Total Patents |
---|---|---|
#1 | Lin Tong-Ho | 23 |
#2 | Wen Yung-Shun | 23 |
#3 | Liang Jui-Wei | 18 |
#4 | Tong-Ho Lin | 2 |
#5 | Jui-Wei Liang | 2 |
#6 | Liu Ying-Ting | 2 |
#7 | Chen Chia-Hsien | 2 |
#8 | Lin Tong Ho | 2 |
#9 | Liang Jui Wei | 2 |
#10 | Wu Zhi-Rong | 2 |
Publication | Filing date | Title |
---|---|---|
TW202042796A | Ketamine pamoate and use thereof | |
WO2020135576A1 | Naltrexone injectable sustained release formulation | |
EP3790881A1 | Long-acting injectable formulations and crystalline forms of buprenorphine derivatives | |
AU2017325910A1 | Sustained-release buprenorphine formulations |